| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CLTCL1 |
| Uniprot No | P53675 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1423-1566aa |
| 氨基酸序列 | LLVLSPRLDHTWTVSFFSKAGQLPLVKPYLRSVQSHNNKSVNEALNHLLTEEEDYQGLRASIDAYDNFDNISLAQQLEKHQLMEFRCIAAYLYKGNNWWAQSVELCKKDHLYKDAMQHAAESRDAELAQKLLQWFLEEGKRECF |
| 预测分子量 | 18.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CLTCL1重组蛋白的3篇参考文献示例(注：文献为虚拟示例，仅供参考)：
1. **文献名称**：*CLTCL1 regulates endosomal sorting through a novel interaction with the retromer complex*
**作者**：Smith A, et al.
**摘要**：本研究利用重组CLTCL1蛋白揭示其与逆转运复合物(retromer)的相互作用，发现CLTCL1通过调控内吞体分选影响膜蛋白回收，为溶酶体降解异常相关疾病提供机制解释。
2. **文献名称**：*Expression and functional characterization of recombinant CLTCL1 in vesicle trafficking*
**作者**：Chen L, et al.
**摘要**：作者在大肠杆菌系统中表达并纯化CLTCL1重组蛋白，证实其通过结合AP2复合物调控网格蛋白包被囊泡形成，影响细胞膜受体(如EGFR)的内吞过程。
3. **文献名称**：*CLTCL1 mutations impair synaptic vesicle recycling in neurological disorders*
**作者**：Wang Y, et al.
**摘要**：通过构建CLTCL1突变体重组蛋白，发现其导致突触小泡循环障碍，与神经元发育异常相关，为神经退行性疾病提供了潜在治疗靶点。
---
**提示**：实际研究中，CLTCL1相关文献多聚焦于其在细胞运输(如内吞、自噬)中的作用，重组蛋白研究可能涉及互作蛋白验证或疾病突变分析。建议通过PubMed/Google Scholar以“CLTCL1 recombinant”或“CLTCL1 clathrin function”为关键词检索最新文献。
CLathrin Heavy Chain Like 1 (CLTCL1), also known as CLTC or CLathrin Heavy Chain 2. is a key component of the clathrin protein family involved in intracellular membrane trafficking and vesicle formation. Clathrin plays a central role in receptor-mediated endocytosis, organelle biogenesis, and synaptic vesicle recycling by forming polyhedral lattices that coat membranes during vesicle budding. CLTCL1 shares structural homology with the canonical clathrin heavy chain (CLTC) but exhibits distinct tissue-specific expression patterns and functional roles. While CLTC is ubiquitously expressed, CLTCL1 is predominantly found in neuronal tissues, endocrine cells, and certain cancers, suggesting specialized regulatory functions in these contexts.
Recombinant CLTCL1 protein is engineered through molecular cloning techniques to enable controlled in vitro studies. Typically produced in prokaryotic (e.g., E. coli) or eukaryotic (e.g., mammalian or insect cell) expression systems, the recombinant protein retains functional domains critical for triskelion assembly, adaptor protein binding, and membrane curvature induction. Its production often includes purification tags (e.g., His-tag) for isolation and biochemical characterization. Researchers utilize recombinant CLTCL1 to investigate its unique interactions with accessory proteins like AP-1/2 complexes, dynamin, and huntingtin-associated proteins, which are essential for understanding its role in neurological disorders, endocrine secretion, and cancer metastasis. Dysregulation of CLTCL1 has been linked to neurodevelopmental defects, tumor progression, and impaired glucose metabolism, making it a potential therapeutic target. Current studies focus on its isoform-specific mechanisms, post-translational modifications, and crosstalk with other trafficking pathways. The availability of recombinant CLTCL1 accelerates structural analysis, drug screening, and functional assays to decipher its pathophysiological significance.
×
